• +1-646-491-9876
    • +91-20-67278686

    Search

    Baculoviral IAP Repeat Containing Protein 5-Pipeline Review H2 2017

    Baculoviral IAP Repeat Containing Protein 5-Pipeline Review H2 2017

    • Report Code ID: RW0001881474
    • Category Life Sciences
    • No. of Pages 62
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Pipeline Review H2 2017

    Summary

    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 18 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Baculoviral IAP Repeat Containing Protein 5-Pipeline Review H2 2017 outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type.

    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia. The molecules developed by companies in Phase II Preclinical and Discovery stages are 3 9 and 1 respectively. Similarly the universities portfolio in Phase II and Preclinical stages comprises 2 and 3 molecules respectively. Report covers products from therapy areas Oncology and Immunology which include indications Prostate Cancer Pancreatic Cancer Bladder Cancer Melanoma Autoimmune Disorders Bone Metastasis Colorectal Cancer Breast Cancer Colon Carcinoma Glioblastoma Multiforme (GBM) Head And Neck Cancer Kidney Cancer (Renal Cell Cancer) Lymphoma Malignant Mesothelioma Metastatic Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Metastatic Lung Cancer Multiple Myeloma (Kahler Disease) Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) Non-Small Cell Lung Cancer Ovarian Cancer and Solid Tumor.

    Furthermore this report also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
    - The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Overview
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Companies Involved in Therapeutics Development
    Biomics Biotechnologies Co Ltd
    Bioneer Corp
    Boehringer Ingelheim GmbH
    MimiVax LLC
    Optimum Therapeutics LLC
    Polyplus-Transfection SA
    Vaxeal Holding SA
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Drug Profiles
    Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BI-1361849-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BKM-1644-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BKM-1740-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target PSA PAP Survivin and hTERT for Metastatic Hormone Refractory Prostate Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug to Target Survivin for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FL-118-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody to Inhibit Survivin for Oncology and Autoimmune Diseases-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MX-106-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SVX-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    UC-112-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Lymphoma and Colon Carcinoma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Survivin for Autoimmune Diseases Glioblastoma Multiforme and Multiple Myeloma-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine to Target Survivin for Breast Cancer and Colorectal Cancer-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Dormant Products
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Discontinued Products
    Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)-Product Development Milestones
    Featured News & Press Releases
    May 31 2016 Clinical Trial Will Explore First-Time Use of SurVaxM Vaccine in Combination with REVLIMID to Treat Rare Blood Cancer
    Sep 09 2015 Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger Multisite Study
    Apr 28 2015 Camptothecin Analog FL118 Can Overcome Treatment Resistance Outperform Approved Therapies
    Apr 21 2015 SurVaxM Phase I Completed
    Dec 15 2014 Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer
    Dec 31 2013 Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    Dec 31 2013 Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent
    Nov 04 2013 CureVac Collaborates with the Cancer Research Institute and Ludwig Cancer Research to Enable Clinical Testing of Novel Immunotherapy Treatment Options for Cancer
    Apr 02 2013 Roswell Park Scientists Advance Findings about Novel Low-Toxicity Anticancer Agent
    Sep 20 2012 RPCI Scientists Publish Findings About Novel Anticancer Agent
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by Biomics Biotechnologies Co Ltd H2 2017
    Pipeline by Bioneer Corp H2 2017
    Pipeline by Boehringer Ingelheim GmbH H2 2017
    Pipeline by MimiVax LLC H2 2017
    Pipeline by Optimum Therapeutics LLC H2 2017
    Pipeline by Polyplus-Transfection SA H2 2017
    Pipeline by Vaxeal Holding SA H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Discontinued Products H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Biomics Biotechnologies Co Ltd
    Bioneer Corp
    Boehringer Ingelheim GmbH
    MimiVax LLC
    Optimum Therapeutics LLC
    Polyplus-Transfection SA
    Vaxeal Holding SA

    Request for Sample

    Report Url http://www.reportsweb.com//baculoviral-iap-repeat-containing-protein-5-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//baculoviral-iap-repeat-containing-protein-5-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//baculoviral-iap-repeat-containing-protein-5-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments